These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Initial Management of Noncastrate Advanced, Recurrent, or Metastatic Prostate Cancer: ASCO Guideline Update: ASCO Guideline Q and A. Virgo KS; Rumble RB; Talcott JA JCO Oncol Pract; 2023 Oct; 19(10):843-846. PubMed ID: 37463395 [No Abstract] [Full Text] [Related]
3. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. Loblaw DA; Virgo KS; Nam R; Somerfield MR; Ben-Josef E; Mendelson DS; Middleton R; Sharp SA; Smith TJ; Talcott J; Taplin M; Vogelzang NJ; Wade JL; Bennett CL; Scher HI; J Clin Oncol; 2007 Apr; 25(12):1596-605. PubMed ID: 17404365 [TBL] [Abstract][Full Text] [Related]
4. Active Surveillance for the Management of Localized Prostate Cancer (Cancer Care Ontario Guideline): American Society of Clinical Oncology Clinical Practice Guideline Endorsement. Chen RC; Rumble RB; Loblaw DA; Finelli A; Ehdaie B; Cooperberg MR; Morgan SC; Tyldesley S; Haluschak JJ; Tan W; Justman S; Jain S J Clin Oncol; 2016 Jun; 34(18):2182-90. PubMed ID: 26884580 [TBL] [Abstract][Full Text] [Related]
5. Outcome predictions for patients with metastatic prostate cancer. Smaletz O; Scher HI Semin Urol Oncol; 2002 May; 20(2):155-63. PubMed ID: 12012302 [TBL] [Abstract][Full Text] [Related]
12. Prostate-specific membrane antigen theranostics in advanced prostate cancer: an evolving option. Mayor N; Sathianathen NJ; Buteau J; Koschel S; Antón Juanilla M; Kapoor J; Azad A; Hofman MS; Murphy DG BJU Int; 2020 Nov; 126(5):525-535. PubMed ID: 32559353 [TBL] [Abstract][Full Text] [Related]
13. Examining initial treatment and survival among men with metastatic prostate cancer: An analysis from the CaPSURE registry. Borno HT; Cowan JE; Zhao S; Broering JM; Carroll PR; Ryan CJ Urol Oncol; 2020 Oct; 38(10):793.e1-793.e11. PubMed ID: 32782182 [TBL] [Abstract][Full Text] [Related]
14. Prognostic Factors for Survival in Noncastrate Metastatic Prostate Cancer: Validation of the Glass Model and Development of a Novel Simplified Prognostic Model. Gravis G; Boher JM; Fizazi K; Joly F; Priou F; Marino P; Latorzeff I; Delva R; Krakowski I; Laguerre B; Walz J; Rolland F; Théodore C; Deplanque G; Ferrero JM; Pouessel D; Mourey L; Beuzeboc P; Zanetta S; Habibian M; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Labourey JL; Machiels JP; El Kouri C; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Soulie M; Oudard S Eur Urol; 2015 Aug; 68(2):196-204. PubMed ID: 25277272 [TBL] [Abstract][Full Text] [Related]
16. [Update of treatment for prostate cancer]. Ito K Gan To Kagaku Ryoho; 2011 Jan; 38(1):48-53. PubMed ID: 21434292 [No Abstract] [Full Text] [Related]
17. Prostate cancer update. Rosenberg J; Small EJ Curr Opin Oncol; 2003 May; 15(3):217-21. PubMed ID: 12778015 [TBL] [Abstract][Full Text] [Related]
18. Current Imaging Techniques for and Imaging Spectrum of Prostate Cancer Recurrence and Metastasis: A Pictorial Review. Tanaka T; Yang M; Froemming AT; Bryce AH; Inai R; Kanazawa S; Kawashima A Radiographics; 2020; 40(3):709-726. PubMed ID: 32196428 [TBL] [Abstract][Full Text] [Related]
19. Clinical protocol: phase I study of an adenovirus/prostate-specific antigen vaccine in men with metastatic prostate cancer. Lubaroff DM; Konety B; Link BK; Ratliff TL; Madsen T; Shannon M; Ecklund D; Williams RD Hum Gene Ther; 2006 Feb; 17(2):220-9. PubMed ID: 16454655 [No Abstract] [Full Text] [Related]